NCI Joins NIH Parent R01 Grant for Clinical Trials
Summary
The National Cancer Institute (NCI) has announced its participation in the NIH Research Project Grant (Parent R01 Clinical Trial Required) funding opportunity, PA-25-305. This participation is effective for the June 5, 2026 due date and subsequent deadlines, allowing NCI to fund clinical trial research through this mechanism.
What changed
The National Cancer Institute (NCI) has issued a notice to inform potential applicants that it will participate in the NIH Research Project Grant (Parent R01 Clinical Trial Required) funding opportunity, PA-25-305. This participation begins with the June 5, 2026, due date and applies to all subsequent deadlines. The NCI's involvement means that grants submitted under PA-25-305 that align with NCI's research priorities will be considered for NCI funding.
This notice does not introduce new compliance obligations for regulated entities but rather clarifies funding pathways for clinical trial research. Researchers and institutions seeking NIH funding for clinical trials should note NCI's participation when preparing applications for the specified due dates. The notice provides contact information for inquiries regarding NCI's participation in this grant program.
What to do next
- Review NCI's participation in PA-25-305 for relevant clinical trial funding opportunities.
- Note the June 5, 2026, due date for applications seeking NCI funding through this R01 opportunity.
Source document (simplified)
Notice of National Cancer Institutes Participation in PA-25-305, NIH Research Project Grant (Parent R01 Clinical Trial Required) Notice Number: NOT-CA-26-009
Key Dates
Release Date: March 25, 2026
Related Announcements
- December 18, 2024 - NIH Research Project Grant (Parent R01 Clinical Trial Required). See NOFO PA-25-305.
Issued by
National Cancer Institute (NCI)
Purpose
The purpose of this notice is to inform potential applicants that the National Cancer Institute (NCI) will participate in PA-25-305 "NIH Research Project Grant (Parent R01 Clinical Trial Required)" effective for the June 5, 2026 due date and subsequent due dates.
The following text has been added to reflect NCI's participation in PA-25-305:
- Part 1. Overview Information Components of Participating Organizations
National Cancer Institute (NCI)
Assistance Listing Number(s)
93.393, 93.394, 93.395, 93.399
Inquiries
Please direct all inquiries to:
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices Department of Health
and Human Services (HHS) NIH... Turning Discovery Into Health ®
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Trade & Sanctions alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when NIH Guide Funding Opportunities publishes new changes.